PressJune 10, 2026 Optimi Health completes first psilocybin export to the United Kingdom for a Phase 2 trial
PressJune 8, 2026 Optimi Health secures naturally derived ibogaine to expand its psychedelic drug portfolio
PressMay 29, 2026 Optimi Health welcomes expanded Australian Authorized Prescriber framework for psilocybin and MDMA
PressMay 21, 2026 GH Research to present new GH001 Phase 2b data in treatment-resistant depression at ASCP 2026
PressMay 11, 2026 Reunion to present full RECONNECT Phase 2 data for luvesilocin in postpartum depression
PressApril 24, 2026 FDA grants Compass rolling NDA review and a National Priority Voucher for COMP360
PressApril 23, 2026 Psyence doses first patient in Phase 2b psilocybin trial for cancer-related adjustment disorder
